Who are 177Lu-DOTATOC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lutetium Lu 177 Dotatate, Intravenous injection of 177Lu-octreotate, Lutetium[177Lu] Oxodotreotide Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/177lu-dotatoc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

177Lu-DOTATOC — Competitive Intelligence Brief

177Lu-DOTATOC (177Lu-DOTATOC) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Peptide receptor radionuclide therapy (PRRT). Area: Oncology.

phase 3 Peptide receptor radionuclide therapy (PRRT) Somatostatin receptor 2 (SSTR2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

177Lu-DOTATOC (177Lu-DOTATOC) — University Hospital, Basel, Switzerland. 177Lu-DOTATOC is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
177Lu-DOTATOC TARGET	177Lu-DOTATOC	University Hospital, Basel, Switzerland	phase 3	Peptide receptor radionuclide therapy (PRRT)	Somatostatin receptor 2 (SSTR2)
Lutetium Lu 177 Dotatate	Lutetium Lu 177 Dotatate	National Cancer Institute (NCI)	marketed	Peptide receptor radionuclide therapy (PRRT)	Somatostatin receptor 2 (SSTR2)
Intravenous injection of 177Lu-octreotate	Intravenous injection of 177Lu-octreotate	Jules Bordet Institute	phase 3	Radiolabeled peptide; peptide receptor radionuclide therapy (PRRT)	Somatostatin receptor 2 (SSTR2)
Lutetium[177Lu] Oxodotreotide Injection	Lutetium[177Lu] Oxodotreotide Injection	Sinotau Pharmaceutical Group	phase 3	Radiolabeled peptide; peptide receptor radionuclide therapy (PRRT)	Somatostatin receptor 2 (SSTR2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Peptide receptor radionuclide therapy (PRRT) class)

National Cancer Institute (NCI) · 1 drug in this class
University Hospital, Basel, Switzerland · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 177Lu-DOTATOC — Competitive Intelligence Brief. https://druglandscape.com/ci/177lu-dotatoc. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab